All In Biotech

Drug Trial Radar · NCT00384189

A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma

A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma

Last checked: Nov 19, 2026Latest source record: Feb 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,080 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,080

Actual

Start

Sep 2006

Primary completion

Aug 2007

Study completion Aug 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Nycomed GmbH
First posted
Oct 5, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy of inhaled ciclesonide at three different dose levels compared with placebo with respect to pulmonary function, asthma symptoms, and use of rescue medication in children aged 6-11 years with asthma. Treatment medication will be administered as follows: ciclesonide or placebo will be inhaled once daily in the evening. The study consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). The study provides further data on safety and tolerability of ciclesonide.

Conditions

  • Asthma

Interventions

  • CiclesonideDrug

    inhaled Ciclesonide

  • PlaceboDrug

    Ciclesonide placebo-matching inhaler

  • SalbutamolDrug

    Salbutamol inhalation powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Morning Peak Expiratory Flow (PEF)Time frame: Baseline and Week 12

Locations

122 sites in 9 countries. Site status is shown where the registry gives one.

  • Altana Pharma/Nycomed

    Plovdiv, Bulgaria

  • Altana Pharma/Nycomed

    Plovdiv, Bulgaria

  • Altana Pharma/Nycomed

    Rousse, Bulgaria

  • Altana Pharma/Nycomed

    Sofia, Bulgaria

  • Altana Pharma/Nycomed

    Vama, Bulgaria

  • Altana Pharma/Nycomed

    Dresden, Germany

  • Altana Pharma/Nycomed

    Freising, Germany

  • Altana Pharma/Nycomed

    Fulda, Germany

  • Altana Pharma/Nycomed

    Homburg, Germany

  • Altana Pharma/Nycomed

    Kassel, Germany

  • Altana Pharma/Nycomed

    Leipzig, Germany

  • Altana Pharma/Nycomed

    Mannheim, Germany

  • Altana Pharma/Nycomed

    Marburg, Germany

  • Altana Pharma/Nycomed

    München, Germany

  • Altana Pharma/Nycomed

    Rosenheim, Germany

  • Altana Pharma/Nycomed

    Schwäbisch Hall, Germany

  • Altana Pharma/Nycomed

    Welzheim, Germany

  • Altana Pharma/Nycomed

    Wesel, Germany

  • Altana Pharma/Nycomed

    Budapest, Hungary

  • Altana Pharma/Nycomed

    Budapest, Hungary

  • Altana Pharma/Nycomed

    Debrecen, Hungary

  • Altana Pharma/Nycomed

    Jászberény, Hungary

  • Altana Pharma/Nycomed

    Kiskunhalas, Hungary

  • Altana Pharma/Nycomed

    Miskolc, Hungary

  • Altana Pharma/Nycomed

    Mosdós, Hungary

  • Altana Pharma/Nycomed

    Mosonmagyaróvár, Hungary

  • Altana Pharma/Nycomed

    Pécs, Hungary

  • Altana Pharma/Nycomed

    Szeged, Hungary

  • Altana Pharma/Nycomed

    Inowrocław, Poland

  • Altana Pharma/Nycomed

    Lodz, Poland

  • Altana Pharma/Nycomed

    Lodz, Poland

  • Altana Pharma/Nycomed

    Lublin, Poland

  • Altana Pharma/Nycomed

    Poznan, Poland

  • Altana Pharma/Nycomed

    Torun, Poland

  • Altana Pharma/Nycomed

    Warsaw, Poland

  • Altana Pharma/Nycomed

    Warsaw, Poland

  • Altana Pharma/Nycomed

    Zawadzkie, Poland

  • Altana Pharma/Nycomed

    Brasov, Romania

  • Altana Pharma/Nycomed

    Bucharest, Romania

  • Altana Pharma/Nycomed

    Bucharest, Romania

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.